FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068854095> ?p ?o ?g. }

• W2068854095 abstract "Background: Endoxifen, the active metabolite of tamoxifen (Tam), is currently being developed as a drug for the treatment of estrogen receptor (ER) + breast cancer (BC). HER2 expression in ER+ BC is associated with Tam resistance, and in vivo Tam administration to mice bearing ER+/HER2+ xenografts stimulates BC growth (Shou, JNCI 2004). In humans, endoxifen is the most important Tam metabolite responsible for inhibiting estrogen induced BC growth (Wu, Cancer Research 2009). CYP2D6 metabolism affects the concentrations (conc) of endoxifen (Stearns, JNCI, 2003) and associated with worse disease free survival (DFS) in Tam treated BC (Goetz, JCO, 2005). We sought to determine the activity of Tam and its metabolites in ER+/HER2+ BC cell lines and to evaluate the role of CYP2D6 metabolism in Tam-treated patients (pts) with ER+/HER2+ BC. Additionally, we sought to determine endoxifen conc in mice administered oral Tam.Methods: MCF7 (parental and HER2-expressing) and BT474 (ER+/HER2+) cells were used to compare the activity of Tam, 4HT, and endoxifen on estrogen- stimulated growth. Oral tam PK were characterized in mice treated with standard dose of Tam (4 mg/kg; 100 μg). Clinical data were obtained via a retrospective analysis of Tam-treated pts with ER+/ HER2+ BC randomized to receive 5 years of Tam (NCCTG 89-30-52). CYP2D6 metabolism (extensive or decreased) was based on CYP2D6 genotype (*3, 4, 6, 10, 17, 41) and co-administration of a CYP2D6 inhibitor (yes/no). HER2 was determined by immunohistochemistry (IHC) or FISH (tumors 0, 1, or 2+ by IHC). The association between CYP2D6 and DFS was assessed using the log-rank test and proportional hazards modeling.Results: Compared to Tam, endoxifen potently inhibited the growth of estrogen- stimulated BT474 cells. In MCF7 cells, expression of HER2 shifted the conc of endoxifen required for 50% inhibition of growth (IC50) from 54 nM (parental) to 131 nM (HER2 expressing). Using the range of conc of Tam and its metabolites observed in humans (Tam, 300-500 nM; 4HT, 5-10 nM; and endoxifen, 10-200 nM), only endoxifen potently inhibited estrogen- stimulated growth of MCF7HER2+ cells and only at conc achievable in CYP2D6 extensive metabolizers (>50nM). In mice, conc of 4HT and endoxifen were below 15 nM following an oral dose of 4 mg/kg. In NCCTG 89-30-52, both CYP2D6 phenotype and HER2 status was determined in 201/256 randomized pts. HER2 was expressed in 23/215 (11%) but not associated with DFS overall (p=0.62). In the HER2+ subset, pts with decreased CYP2D6 metabolism (n=10) had significantly shorter DFS compared to extensive metabolizers (n=9) (HR 9.5, p=0.03; 95% CI 1.16-76.9).Conclusions: Our in vitro and clinical data provide a simple pharmacological model for understanding HER2 resistance in Tam-treated breast cancer. Mice, which lack the CYP2D6 enzyme, may not be an appropriate model for understanding tam resistance given low conc of both 4HT and endoxifen. Given that the in vitro conc of endoxifen needed to inhibit the growth of ER+/HER-2+ BC are achievable in only a subset of humans (CYP2D6 extensive metabolizers), the primary administration of endoxifen could overcome de novo Tam resistance in ER+/HER2+ BC. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2006." @default.
• W2068854095 created "2016-06-24" @default.
• W2068854095 creator A5003292200 @default.
• W2068854095 creator A5008665323 @default.
• W2068854095 creator A5012302982 @default.
• W2068854095 creator A5026706928 @default.
• W2068854095 creator A5027416118 @default.
• W2068854095 creator A5029345886 @default.
• W2068854095 creator A5039405117 @default.
• W2068854095 creator A5047808879 @default.
• W2068854095 creator A5055673436 @default.
• W2068854095 creator A5059553628 @default.
• W2068854095 creator A5060720802 @default.
• W2068854095 creator A5066722006 @default.
• W2068854095 creator A5082661564 @default.
• W2068854095 date "2009-12-15" @default.
• W2068854095 modified "2023-09-26" @default.
• W2068854095 title "Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+ Breast Cancer." @default.
• W2068854095 doi "https://doi.org/10.1158/0008-5472.sabcs-09-2006" @default.
• W2068854095 hasPublicationYear "2009" @default.
• W2068854095 type Work @default.
• W2068854095 sameAs 2068854095 @default.
• W2068854095 citedByCount "1" @default.
• W2068854095 crossrefType "proceedings-article" @default.
• W2068854095 hasAuthorship W2068854095A5003292200 @default.
• W2068854095 hasAuthorship W2068854095A5008665323 @default.
• W2068854095 hasAuthorship W2068854095A5012302982 @default.
• W2068854095 hasAuthorship W2068854095A5026706928 @default.
• W2068854095 hasAuthorship W2068854095A5027416118 @default.
• W2068854095 hasAuthorship W2068854095A5029345886 @default.
• W2068854095 hasAuthorship W2068854095A5039405117 @default.
• W2068854095 hasAuthorship W2068854095A5047808879 @default.
• W2068854095 hasAuthorship W2068854095A5055673436 @default.
• W2068854095 hasAuthorship W2068854095A5059553628 @default.
• W2068854095 hasAuthorship W2068854095A5060720802 @default.
• W2068854095 hasAuthorship W2068854095A5066722006 @default.
• W2068854095 hasAuthorship W2068854095A5082661564 @default.
• W2068854095 hasConcept C121608353 @default.
• W2068854095 hasConcept C126322002 @default.
• W2068854095 hasConcept C143998085 @default.
• W2068854095 hasConcept C149151106 @default.
• W2068854095 hasConcept C2777164284 @default.
• W2068854095 hasConcept C2777176818 @default.
• W2068854095 hasConcept C2777477808 @default.
• W2068854095 hasConcept C33664856 @default.
• W2068854095 hasConcept C526171541 @default.
• W2068854095 hasConcept C530470458 @default.
• W2068854095 hasConcept C62231903 @default.
• W2068854095 hasConcept C71924100 @default.
• W2068854095 hasConcept C84606932 @default.
• W2068854095 hasConcept C98274493 @default.
• W2068854095 hasConceptScore W2068854095C121608353 @default.
• W2068854095 hasConceptScore W2068854095C126322002 @default.
• W2068854095 hasConceptScore W2068854095C143998085 @default.
• W2068854095 hasConceptScore W2068854095C149151106 @default.
• W2068854095 hasConceptScore W2068854095C2777164284 @default.
• W2068854095 hasConceptScore W2068854095C2777176818 @default.
• W2068854095 hasConceptScore W2068854095C2777477808 @default.
• W2068854095 hasConceptScore W2068854095C33664856 @default.
• W2068854095 hasConceptScore W2068854095C526171541 @default.
• W2068854095 hasConceptScore W2068854095C530470458 @default.
• W2068854095 hasConceptScore W2068854095C62231903 @default.
• W2068854095 hasConceptScore W2068854095C71924100 @default.
• W2068854095 hasConceptScore W2068854095C84606932 @default.
• W2068854095 hasConceptScore W2068854095C98274493 @default.
• W2068854095 hasLocation W20688540951 @default.
• W2068854095 hasOpenAccess W2068854095 @default.
• W2068854095 hasPrimaryLocation W20688540951 @default.
• W2068854095 hasRelatedWork W1558111333 @default.
• W2068854095 hasRelatedWork W2028688029 @default.
• W2068854095 hasRelatedWork W2034477598 @default.
• W2068854095 hasRelatedWork W2069898342 @default.
• W2068854095 hasRelatedWork W2089941912 @default.
• W2068854095 hasRelatedWork W2138599916 @default.
• W2068854095 hasRelatedWork W2158939948 @default.
• W2068854095 hasRelatedWork W2312452070 @default.
• W2068854095 hasRelatedWork W2315032103 @default.
• W2068854095 hasRelatedWork W2328982042 @default.
• W2068854095 hasRelatedWork W2343993019 @default.
• W2068854095 hasRelatedWork W2357469295 @default.
• W2068854095 hasRelatedWork W2362322902 @default.
• W2068854095 hasRelatedWork W2471812418 @default.
• W2068854095 hasRelatedWork W2505717779 @default.
• W2068854095 hasRelatedWork W2910788216 @default.
• W2068854095 hasRelatedWork W2999386466 @default.
• W2068854095 hasRelatedWork W3151135580 @default.
• W2068854095 hasRelatedWork W398790120 @default.
• W2068854095 hasRelatedWork W602580784 @default.
• W2068854095 isParatext "false" @default.
• W2068854095 isRetracted "false" @default.
• W2068854095 magId "2068854095" @default.
• W2068854095 workType "article" @default.